Biomea Fusion (BMEA) Shares Outstanding (2020 - 2026)
Biomea Fusion (BMEA) posted Shares Outstanding (Entity) of $72.3 million for Q1 2026, up 38.43% sequentially from $52.2 million in Q4 2025, and up 92.43% YoY from $37.6 million in Q1 2025.
Biomea Fusion (BMEA) Shares Outstanding (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $72.3 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 92.43% year-over-year to $72.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.3 million (up 92.43% YoY) and the FY2025 annual result came in at $52.2 million, up 43.84% from the prior year.
- Shares Outstanding (Entity) climbed to $72.3 million in Q1 2026 per BMEA's latest filing, from $52.2 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $72.3 million in Q1 2026 and troughed at $29.2 million in Q1 2022.
- A 5-year average of $38.9 million and a median of $35.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 142.98% in 2022, down 1.0% in 2022.
- Over 5 years, Shares Outstanding (Entity) stood at $29.6 million in 2022, then rose by 21.33% to $35.9 million in 2023, then climbed by 1.24% to $36.3 million in 2024, then surged by 43.84% to $52.2 million in 2025, then soared by 38.43% to $72.3 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $72.3 million, $52.2 million, and $59.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 72.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.36 Mn |
| Mar 31, 2026 | 72.30 Mn |
| Dec 31, 2025 | 52.23 Mn |
| Sep 30, 2025 | 59.85 Mn |
| Jun 30, 2025 | 40.63 Mn |
| Mar 31, 2025 | 36.63 Mn |
| Dec 31, 2024 | 36.11 Mn |
| Sep 30, 2024 | 36.22 Mn |
| Jun 30, 2024 | 36.04 Mn |
| Mar 31, 2024 | 35.89 Mn |
| Dec 31, 2023 | 34.11 Mn |
| Sep 30, 2023 | 35.65 Mn |
| Jun 30, 2023 | 35.35 Mn |
| Mar 31, 2023 | 29.59 Mn |
| Dec 31, 2022 | 29.27 Mn |
| Sep 30, 2022 | 29.32 Mn |
| Jun 30, 2022 | 29.20 Mn |
| Mar 31, 2022 | 29.13 Mn |
| Dec 31, 2021 | 23.86 Mn |
| Sep 30, 2021 | 29.00 Mn |